News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-11-11 EST			5-day change	1st Jan Change
46.60 ^USD	-2.92%		+1.11%	+5.79%

11-10	Scholar Rock Holding Corporation, Q3 2026 Earnings Call, Nov 10, 2026
11-10	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid October Consumer Inflation Report	MT

All News

Mentions Relevance

b6d7b546bb91143d.b-_nBuIPsEoKOo37XSFRsWc77tVEbyfDhtFdGRdCzes.AZ7VWdZawjxfa8qVE0oriFJ-gpwQCXKFzLNqaCII_9wVpK9A1UblDENd-g

11-10	Scholar Rock Holding Corporation, Q3 2026 Earnings Call, Nov 10, 2026
11-10	Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-10	Scholar Rock's Q3 Net Loss Narrows, Registers Revenue; Shares Drop Pre-Bell	MT
11-10	Earnings Flash (SRRK) Scholar Rock Holding Corporation Reports Q3 Revenue $570,000	MT
11-10	Earnings Flash (SRRK) Scholar Rock Posts Q3 Loss of $0.81 a Share, vs. FactSet Est of $0.85 Loss	MT
11-10	Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights	BU
11-03	Scholar Rock to Present at Upcoming Investor Conferences	BU
10-28	Scholar Rock Holding Insider Bought Shares Worth $11,999,922, According to a Recent SEC Filing	MT
10-20	Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026	BU
10-16	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10-08	Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy	MT
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)	BU
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application To European Medicines Agency For Treatment Of Children And Adults With Spinal Muscular Atrophy	CI
09-25	Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says	MT
09-24	Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating	MT
09-21	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09-15	Scholar Rock Shares Fall After Barclays Downgrade	MT
09-15	Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says	MT
09-15	Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55	MT
09-14	Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says	MT
09-14	Wedbush Adjusts Price Target on Scholar Rock to $70 From $64, Keeps Outperform Rating	MT
09-14	Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)	AQ
09-14	Scholar Rock Holding Corporation - Special Call
09-14	Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually	RE
09-14	Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial	RE